This complementary and alternative medicine (CAM) information summary provides an overview of the use of milk thistle as a treatment and adjunct agent for people with cancer.
The summary includes a brief history of milk thistle, a review of the laboratory studies and clinical trials, and a description of adverse effects associated with milk thistle use.
This summary contains the following key information:
Milk thistle is a plant whose fruit and seeds have been used for more than 2,000 years...
Endometrial cancer is the most common invasive gynecologic cancer in U.S. women, with an estimated 49,560 new cases expected to occur in 2013. This disease primarily affects postmenopausal women at an average age of 60 years at diagnosis. In the United States, it is estimated that approximately 8,190 women will die of endometrial cancer in 2013. Incidence rates of endometrial cancer have been increasing by an average of 1.1% per year from 2004 to 2008. Death rates from cancer of the uterine corpus have been increasing by an average of 0.3% per year from 1998 to 2007.
In the mid-1970s, the diagnosis of approximately 15,000 cases of postmenopausal endometrial cancers in excess of those expected on the basis of the underlying secular trend, has been related to the use of postmenopausal estrogen therapy. Additional risk factors may be related to estrogenic effects, including obesity, a high-fat diet, polycystic ovarian syndrome, tamoxifen use and reproductive factors such as nulliparity, early menarche, and late menopause.
Women with hereditary nonpolyposis colorectal cancer (HNPCC) syndrome have a markedly increased risk of endometrial cancer compared with women in the general population. Among women who are HNPCC mutation carriers, the estimated cumulative incidence of endometrial cancer ranges from 20% to 60%.[5,6]
Compared with white Americans, endometrial cancer incidence is lower in Japanese Americans (relative risk [RR] = 0.6; 95% confidence interval [CI], 0.46–0.83) and in Latinas (RR = 0.63; 95% CI, 0.46–0.87), but not in African Americans (RR = 0.76; 95% CI, 0.53–1.08) or in native Hawaiians (RR = 0.92; 95% CI, 0.58–1.46). Higher mortality from endometrial cancer in African Americans is at least partly attributable to lower socioeconomic issues that impair access to care.
Factors that have been associated with a decreased incidence of endometrial cancer include parity, lactation, use of combined oral contraceptives, a diet low in fat and high in plant foods, and physical activity.